Literature DB >> 11436038

Human angiopoietin gene expression is a marker for severity of pulmonary hypertension in patients undergoing pulmonary thromboendarterectomy.

P A Thistlethwaite1, S H Lee, L L Du, P L Wolf, C Sullivan, S Pradhan, R Deutsch, S W Jamieson.   

Abstract

OBJECTIVE: A consistent pathologic feature seen in lungs of patients with pulmonary hypertension from thromboembolic disease is hyperplasia of the media of pulmonary arterioles. The molecular factors responsible for these vessel wall changes are unknown. Angiopoietin-1 is a gene responsible for the formation of the media of blood vessels in utero. We hypothesized that aberrant expression of the angiopoietin-1 gene in the adult lung would be a major contributing factor in the development of pulmonary hypertension.
METHODS: From April 1999 to March 2000, a total of 35 patients (18 men, 17 women, mean age 52 years) with pulmonary hypertension and pulmonary vascular resistance ranging from 407 to 2006 dynes x sec x cm(-5) underwent pulmonary endarterectomy at our institution. Before cardiopulmonary bypass, lung biopsy specimens were taken from each patient. Biopsy specimens were also obtained from 10 patients (5 women, 5 men, mean age 55 years) undergoing lung resection for causes other than pulmonary hypertension. All specimens were blindly scored by a pathologist for degree of medial hyperplasia. Quantitative reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry were used to quantitate angiopoietin-1 messenger RNA and protein in each sample.
RESULTS: Lung specimens from all patients with pulmonary hypertension demonstrated up-regulation of angiopoietin-1 at the messenger RNA level. The degree of angiopoietin-1 transcription was directly proportional to the preoperative pulmonary vascular resistance and medial wall hyperplasia/hypertrophy in each patient. By immunohistochemistry, angiopoietin-1 protein was confined to the media of pulmonary arterioles. Lung biopsy specimens from patients without pulmonary hypertension had no detectable expression of angiopoietin-1 at the messenger RNA or protein level.
CONCLUSION: Angiopoietin-1, a gene responsible for vessel development in the embryonic lung, is up-regulated in the lung parenchyma of patients with pulmonary hypertension. The level of expression of angiopoietin-1 at messenger RNA and protein levels correlates to the severity of pulmonary hypertension in patients with thromboembolic disease and serves as a target for strategies to treat this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436038     DOI: 10.1067/mtc.2001.113753

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

Review 1.  Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability.

Authors:  Yulia A Komarova; Kevin Kruse; Dolly Mehta; Asrar B Malik
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

2.  Serum levels of angiopoietin-1 in patients with pulmonary hypertension due to mitral stenosis.

Authors:  Hekim Karapınar; Ozlem Esen; Yunus Emiroğlu; Mustafa Akçakoyun; Selçuk Pala; Ramazan Kargın; Akın Izgi; Cevat Kirma; Ali Metin Esen
Journal:  Heart Vessels       Date:  2010-12-08       Impact factor: 2.037

3.  Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension.

Authors:  Yu Ji Cho; Jae Yoon Han; Sang Gab Lee; Byeong Tak Jeon; Wan Sung Choi; Young Sil Hwang; Gu Seob Roh; Jong Deog Lee
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

4.  MicroRNA-150 Suppression of Angiopoetin-2 Generation and Signaling Is Crucial for Resolving Vascular Injury.

Authors:  Charu Rajput; Mohammad Tauseef; Mohammad Farazuddin; Pascal Yazbeck; Md-Ruhul Amin; Vijay Avin Br; Tiffany Sharma; Dolly Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-07       Impact factor: 8.311

5.  Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome.

Authors:  Diana C Gallagher; Samir M Parikh; Konstantin Balonov; Andrew Miller; Shiva Gautam; Daniel Talmor; Vikas P Sukhatme
Journal:  Shock       Date:  2008-06       Impact factor: 3.454

Review 6.  A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Authors:  Gerald Maarman; Sandrine Lecour; Ghazwan Butrous; Friedrich Thienemann; Karen Sliwa
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

7.  The actuarial survival analysis of the surgical and non-surgical therapy regimen for chronic thromboembolic pulmonary hypertension.

Authors:  Hui-Li Gan; Jian-Qun Zhang; Ping Bo; Qi-Wen Zhou; Sheng-Xun Wang
Journal:  J Thromb Thrombolysis       Date:  2009-04-11       Impact factor: 2.300

Review 8.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

9.  Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy.

Authors:  Sami I Said; Sayyed A Hamidi
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

10.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.